RHYTHM PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Convertible Preferred Stock & Stockholders’ Equity

(in thousands, except share data)

Series A ConvertiblePreferred Stock · Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount · Shares · Amount
Balance at December 31, 2022	—	$—		56,612,429		$56		$974,356		$(92)		$(710,058)		$264,262
Stock compensation expense	—	—		—		—		32,553		—		—		32,553
Issuance of common stock in connection with ESPP	—	—		49,819			1,053		—		—		1,053
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	—	—		745,066		1		7,467		—		—		7,468
Issuance of common stock upon completion of ATM equity offering, net of offering costs	—	—		2,019,245		2		48,873		—		—		48,875
Foreign currency translation adjustment	—	—		—		—		—		(140)		—		(140)
Net unrealized gain on marketable securities	—	—		—		—		—		366		—		366
Net loss	—	—		—		—		—		—		(184,678)		(184,678)
Balance at December 31, 2023	—	$—		59,426,559		$59		$1,064,302		$134		$(894,736)		$169,759
Issuance of Series A Preferred Stock, net of $2.3 million of issuance costs	150,000	138,850		—		—		—		—		—		—
Stock compensation expense	—	—		—		—		39,682		—		—		39,682
Issuance of common stock in connection with ESPP	—	—		44,554		—		1,270		—		—		1,270
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	—	—		1,742,803		2		15,972		—		—		15,974
Issuance of common stock as consideration for LGC license	—	—		432,143		—		18,716		—		—		18,716
Issuance of common stock upon completion of ATM equity offering, net of $1.1 million offering costs	—	—		744,595		—		41,073		—		—		41,073
Accretion of preferred stock dividends	—	3,970		—		—		(3,970)		—		—		(3,970)
Foreign currency translation adjustment	—	—		—		—		—		2		—		2
Net unrealized loss on marketable securities	—	—		—		—		—		(175)		—		(175)
Net loss	—	—		—		—		—		—		(260,602)		(260,602)
Balance at December 31, 2024	150,000	$142,820		62,390,654		$61		$1,177,045		$(39)		$(1,155,338)		$21,729
Stock compensation expense	—		—		—		—		66,818		—		—		66,818
Issuance of common stock in connection with ESPP	—		—		37,514		1		1,583		—		—		1,584
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	—		—		1,457,414		1		13,603		—		—		13,604
Issuance of common stock upon completion of public offering, net of offering costs of $12.6 million	—		—		2,367,647		2		188,655		—		—		188,657
Issuance of common stock upon completion of ATM equity offering, net of $0.7 million of offering costs	—		—		587,510		1		32,108		—		—		32,109
Accretion of preferred stock dividends	—		5,378		—		—		(5,378)		—		—		(5,378)
Conversion of Series A preferred stock redeemable to common stock	(17,500)		(17,241)		364,582		1		17,241		—		—		17,242
Foreign currency translation adjustment	—		—		—		—		—		(1,261)		—		(1,261)
Net unrealized gain on marketable securities	—		—		—		—		—		504		—		504
Net loss	—		—		—		—		—		—		(196,539)		(196,539)
Balance at December 31, 2025	132,500	$130,957		67,205,321		$67		$1,491,675		$(796)		$(1,351,877)		$139,069

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.